LG Life Science to add adverse reactions to Calvan

Published: 2005-07-25 07:00:00

Updated: 2005-07-25 07:00:00

LG Life Science announced that the adverse reactions such as hypotension, dyspepsia, abdominal pain and impotence should be added to the label of Calvan 50mg (bevantolol) as a result of its drug review by the KFDA.

The additional labelling of adverse reactions has been instructed as resulted ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK